Wintest
6721
Showcase
3909
Beauty Kadan Holdings
3041
Cybozu
4776
KODAMA CHEMICAL INDUSTRY
4222
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.41%9.36B | -3.96%37.15B | -1.54%10.83B | -6.57%9.18B | -4.10%8.95B | -3.91%8.18B | 16.79%38.68B | 15.04%11B | 15.87%9.82B | 20.78%9.34B |
Cost of revenue | 11.60%5.82B | -6.37%23.66B | -4.87%7.02B | -9.87%5.74B | -5.25%5.68B | -5.54%5.21B | 15.44%25.27B | 14.22%7.38B | 14.51%6.37B | 17.91%6B |
Gross profit | 19.34%3.54B | 0.58%13.49B | 5.24%3.81B | -0.48%3.43B | -2.04%3.27B | -0.91%2.97B | 19.41%13.41B | 16.73%3.62B | 18.48%3.45B | 26.31%3.34B |
Operating expense | 9.65%2.07B | 5.40%7.77B | 10.60%2.13B | 4.90%1.94B | -2.96%1.81B | 9.14%1.89B | 14.82%7.38B | 12.81%1.93B | 11.82%1.85B | 19.85%1.87B |
Staff costs | ---- | 6.74%2.58B | ---- | ---- | ---- | ---- | 8.56%2.42B | ---- | ---- | ---- |
Research and development costs | ---- | 17.21%984.65M | ---- | ---- | ---- | ---- | 7.20%840.07M | ---- | ---- | ---- |
Other operating expenses | ---- | 2.20%4.21B | ---- | ---- | ---- | ---- | 20.67%4.12B | ---- | ---- | ---- |
Operating profit | 36.30%1.47B | -5.30%5.71B | -0.85%1.68B | -6.70%1.5B | -0.87%1.46B | -14.67%1.08B | 25.53%6.03B | 21.53%1.7B | 27.22%1.6B | 35.59%1.47B |
Net non-operating interest income (expenses) | -31.46%-17.03M | -55.33%-51.06M | -15.22%-11.43M | -57.35%-12.53M | -59.51%-14.15M | -111.69%-12.95M | -11.36%-32.87M | -69.29%-9.92M | -9.73%-7.96M | -9.90%-8.87M |
Non-operating interest income | ---- | -6.91%1.63M | ---- | ---- | ---- | ---- | 4.79%1.75M | ---- | ---- | ---- |
Non-operating interest expense | 31.46%17.03M | 52.18%52.69M | 11.90%13.06M | 57.35%12.53M | 59.51%14.15M | 111.69%12.95M | 11.01%34.62M | 54.99%11.67M | 9.73%7.96M | 9.90%8.87M |
Net investment income | 32.18%153.41M | -23.59%248.08M | 415.18%124M | -74.51%-51.22M | -48.33%59.24M | -46.09%116.06M | 127.22%324.66M | -74.98%24.07M | -152.54%-29.35M | 2,805.74%114.64M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -98.46%736K | -70.76%12M | -11.26M | 1,346.40%47.81M | 1,367,700.00%41.03M | 0 | ||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -100.57%-868K | 642.40%136.32M | -20.12%-7.65M | 34.73%-10.96M | 647.56%1.8M | 9,472.28%153.14M | -663.77%-25.13M | -514.46%-6.37M | -193.72%-16.8M | 85.28%-328K |
Less:Restructuring and mergern&acquisition | ---- | --0 | --0 | ---- | ---- | ---- | -46.02%7.96M | -99.60%17K | ---- | ---- |
Less:Other special charges | 100.57%868K | -893.81%-136.32M | 20.44%7.65M | 23.80%10.96M | -647.56%-1.8M | -9,472.28%-153.14M | 189.43%17.17M | 298.04%6.36M | 131.16%8.86M | -85.28%328K |
Other non-operating income (expenses) | -64.52%11.28M | 38.61%197.78M | 144.43%53.05M | 81.47%102.81M | -63.19%10.13M | -13.65%31.79M | 82.41%142.69M | 6.82%21.7M | 365.66%56.66M | 90.61%27.51M |
Income before tax | 18.32%1.62B | -3.78%6.25B | 4.81%1.85B | -5.80%1.51B | -5.93%1.51B | -9.40%1.37B | 29.85%6.49B | 17.37%1.77B | 19.93%1.61B | 48.48%1.61B |
Income tax | 13.06%533.85M | -4.99%1.88B | 5.91%437.11M | 1.54%507.17M | -19.44%463.8M | -3.85%472.19M | 36.50%1.98B | 21.19%412.71M | 19.73%499.46M | 60.86%575.69M |
Net income | 21.10%1.08B | -3.25%4.37B | 4.47%1.42B | -9.11%1B | 1.59%1.05B | -12.08%895.23M | 27.14%4.51B | 16.25%1.35B | 20.02%1.11B | 42.38%1.03B |
Net income continuous operations | 21.10%1.08B | -3.25%4.37B | 4.47%1.42B | -9.11%1B | 1.59%1.05B | -12.08%895.23M | 27.14%4.51B | 16.25%1.35B | 20.02%1.11B | 42.38%1.03B |
Noncontrolling interests | 26.54%281.69M | -7.73%935.07M | 20.31%273.4M | -18.54%212.5M | -11.93%226.57M | -16.95%222.61M | 34.40%1.01B | 15.81%227.24M | 25.26%260.86M | 60.87%257.26M |
Net income attributable to the company | 19.30%802.41M | -1.95%3.43B | 1.28%1.14B | -6.20%792.4M | 6.07%823.69M | -10.34%672.62M | 25.18%3.5B | 16.34%1.13B | 18.49%844.79M | 37.16%776.58M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 19.30%802.41M | -1.95%3.43B | 1.28%1.14B | -6.20%792.4M | 6.07%823.69M | -10.34%672.62M | 25.18%3.5B | 16.34%1.13B | 18.49%844.79M | 37.16%776.58M |
Gross dividend payment | ||||||||||
Basic earnings per share | 19.30%78.21 | -1.96%334.38 | 1.27%111.3 | -6.19%77.24 | 6.06%80.28 | -10.34%65.56 | 25.18%341.05 | 16.35%109.9 | 18.49%82.34 | 37.14%75.69 |
Diluted earnings per share | 19.30%78.21 | -1.96%334.38 | 1.28%111.3 | -6.20%77.2339 | 6.06%80.28 | -10.34%65.56 | 25.18%341.05 | 16.34%109.8966 | 18.49%82.3396 | 37.16%75.69 |
Dividend per share | 0 | 16.67%70 | 16.67%70 | 0 | 0 | 0 | 33.33%60 | 33.33%60 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |